<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 348 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page347.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=348">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 348 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 348</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=348"><img src="../thumb/348.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Endocrine System - 19.8                                                        2020-04 / 311
       sev. chang., meds.metabol.by cytochrome P450, monit.prothromb.  cycle. Dos. regimen to be follow.every menstr.cycle. Dos. maybe   Drug interactions: Act.of anticoags.poss. potent., cyclospor.incr.
       time with concom.coumar. anticoags.  reduc.to 1-½ tab.dly.on clinic. improvem.  nephrotox.risk, poss.reduc. maint. requirm.of alfacalcidol ther.in hy-
       Drug interactions: Concom.meds.that may inhib oxidat.of agent   Post-menopaus.& aft.hysterect: ½-1 tab dly for 21 days depend.  poparathyroid., oestrog.& progester.poss.modify act.
       eg.ketoconazole & cimetidine theoretic.incr.plasma conc., poss.dis-  on sev.with 7 day treatm.free interv.  DOSTINEX, Pfizer [P/S]
       plac.warfar.from its prot.bind.sites.  Contraindications: Pregn.& lactat., sev.chron. depress., sev.diabet.  Cabergoline.
       CASODEX, AstraZeneca [P/S]    with vasc.chang., Dubin Johns./Rotor syndr., herpes gestationis hist.,   Indications: Inhibit.lactat.bef.breastfeed.& inhibit.est.lactat.for
                                     persist. itch./jaund.hist.dur.prev.pregn., ac.liv.dis., prev./ exist.liv.tu-
       Bicalutamide.                 mours if not due to metastas., wasting dis.except Ca prostate, sickle-  medic.reasons, hyperprolactinaem. disords.
       Indications: Advanc.prostate Ca in combin.with LHRH analogue   cell anaem., hist.of/ exist.thrombo-embol.process., youths und. 18   (S4) TABS. 28/21.12/0244.
       ther./surg.castrat.           yrs.or those whose bone maturat.& testicul. developm.are incompl.  842109-005: 0,5 mg, 2, R220,51
       (S4) TABS. 30/21.12/0012.                                  842109-013: 0,5 mg, 4, R441,03
       822566-001: 50 mg, 30, R3 177,44  Side effects: Decr.male fertil., abnorm.sperm product., gynaeco-  Dosage: Admin.pref.with meals.
                                     mast., galactorrh., benign nodul., hepatit., jaund., hepat.fail., liv.
       Dosage: Begin 3 days bef.LHRH ther./same time as surg.castrat.  Lactat: inhibit: Admin.1 mg as a sngl.dos.dur.1st day post-partum.
       Adult males incl.elderly: 1 tab once dly.  tumours with intra-abdom. haemorrh., inhibit.ovulat.in women,   Suppress est.lactat: 0,25 mg 12 hrly x2 days, max. sngl.
                                     breast tendern., bld.dyscras., breathlessn., chang.in body mass,
       (S4) TABS. 33/21.12/0081      alter.hair pattern, skin reacts., osteoporos., CNS effs., tiredn.,   dos.0,25 mg due to reduc.tolerabil.
       869872-001: 150 mg, 30, R6 982,43                          Hyperprolactinaemia: Init.0,5 mg as 1 or 2 dos. wkly.incr.by 0,5 mg
       Indications: Loc.advanc.non-metastat.prostate Ca where surg./  adrenocort.suppress.  at mnth.interv.until optim. therapeut.respons.achiev. Therapeut.
                                     Special precautions: Reduc.grad., women of child-bear.age also
       med.castrat.inappropr., loc.advanc. metastat.prostate Ca alone   dos: 1 mg/ wk. rang.from 0,25-2 mg/wk.max.4,5 mg/wk.in div.dos.
       where surg./med. castrat.inappropr.  to use addit.non-horm. contracept. methods dur.first 3 wks.of cy-  Contraindications: Pregn.& breast feed., pre-eclamp.or post-
       Dosage: Adult males incl.elderly: 150 mg once dly for 2 yrs   cle, prostat. Ca pts.with thromoboembol.hist.and/or exist. sickle   partum hypertens., safety & effic. in ren./hepat.dis.or pts less than
                                     cell anaem./diab.with vasc. chang., thorough exam.advis.& pregn.
       or unt.progress.                                           16 yrs not est., concom.meds.which have dopam.antagon.activ.
       Contraindications: Fem., childr., pregn.& lactat.  excl. bef.init. ther., monit. liv. funct.pre-treatm. & if S&S suggest.   Side effects: Pleur.effus./pulm.fibros., valvulopathy with longt.use,
       Side effects: Gynaecomast., breast tendern./ pain., GI disturbs., hot   of hepatotoxic., discont. treatm.if cyproterone-induc. hepatotoxic.   decr.BP, vasoconstrict. eff, CNS eff., headache, trans. haemianops.,
       flush., prurit., asthen., alopec., hair re-growth, dry skin, decr.libido,   occurs, bear in mind that sex.steroids can promote growth of cert.  palpitat., epistax., GI disturbs., dizzin., vertigo, syncope, hot flush., as-
       impot., weight gain/loss, CV/CNS effs., sev. hepatotoxic., haema-  horm. depend.tiss.& tumours., excl.liv.tumour if sev.upper GI sympt.&   then., paraesthes., breast pain., faint., vasosp., leg cramp., depress.
       tur., interstit.lung dis., liv. chang., thrombocytopen., dyspn., noctur.,   S&S intra-abdom.haemorrh.occur, heavy/incr. bleed. in women,   Warnings and special precautions: Eval.pituit. funct. bef.init.
       anaem., rash, sweat., hirsut., diab., hyperglycaem., oed., abdom./  ischaem.heart dis., cerebrovasc. dis., hypertens., CV dis., diabet.,   treatm., hist./curr.signs &/sympt.of resp./ card.disords.link.to fibrot.
       chest/pelv.pain, headache, chills, hypersens. reacts.incl.angio-oed.  monit.adrenocort. funct. reg., if poss.do not give bef.end of puberty.  tiss, concom.ergot. alkal. not recomm., concom.use with agents
       Special precautions: Mod.to sev.hepat. impairm., period.liv.funct.  Drug interactions: Sex.drive reduc.eff.dimin.by alcoh.  which have dopamine antagon.activ., excl.pregn.bef.init. treatm. &
       tests advis., disont.ther.if hepatotox. chang.sev., poss.anti-androg.  CIPLA LETROZOLE, Cipla Medpro  prev.for at least mnth.aft., monit.ser. prolact. levels mnthly., liv.dis.,
                                                                  elderly with hyperprolactinaem. disords., CV dis., Raynaud’s syndr.,
       withdr. syndr. with discont., monit.prothromb.time with concom.   Letrozole
       coumar.anticoags.             Indications: Extend.adjuvant treatm.of early breast Ca in post men-  ren.insuf., pept.ulc., psych.disords./GI bleed. hist., monit.B/P, con-
                                                                  com.BP low.agents, mnthly. pregn.tests dur.treatm.& 3 days aft.
       Drug interactions: Concom.meds.that may inhib. oxidat. of agent   opaus.women who have rec.prior std. adjuvant tamoxifen ther., first
       eg.ketoconazole & cimetidine which could theoretic.incr.plasma   line treatm.in postmenpaus. women with hormone depend.advanc.  delay. menstruat., monit.pituit.size aft.confirm.pregn.dur. treatm.
       conc., concom. meds. with narr.therapeut.index e.g. terfenadine,   breast Ca, advanc.breast Ca in women with natural/artific. induc.  Drug interactions: Prolact.low.eff.poss.reduc.by agents
       astemizole, cisapride & cyclosporin., poss. displacem. of warfar.  postmenopaus. status prev.treat.with anti-oestrog., pre-op ther.in   which have dopamine antagon.activ., macrolide antibiot.incr.
       from its prot.bind.sites.     postmenopaus.women with localis.horm.recept. positive breast   bioavailabil.
       CETROTIDE, Merck [P/S] &      Ca allow.subseq.breast-conserv. surg.in women not origin.consid.  DUODART, (Aspen Pharmacare) GSK &
       Cetrorelix                    for this type of surg.       Dutasteride 0,5 mg, tamsulosin HCl 0,4 mg
                                                                  Indications: Mod.to sev.benign prostat. hyperplas. sympt.treatm.
       Indications: Prev.of premat.ovulat.in control. ovar.stimulat.follow.  (S4) TABS, 44/21.12/0282
       by oocyte pick-up & assist. reproduct.techniques.  718349-001: 2,5 mg, 30, R517,58  (S4) CAPS, 44/21.12/0850
                                                                  723166-001: 30, R457,20
       (S4) INJ. A39/21.12/0064, A40/34/0162  Dosage: Adults & elderly: 2,5 mg once dly. Contin. x5 yrs./until   Dosage: Swall. whole & not chew./open. Contact with contents of
                                                       st
       710346-001: 0,25 mg, 1 vial+solv.in pre-fill.syr., R463,70  tumour relapse occurs/ whichever comes 1 . Contin until tumour   caps.poss.result.in oropharyng. mucosa irrit.
       Dosage: Use by exper.physic.only. Use only suppl. solv./water for   progress. is evident in metast.dis.pts.  Adult males incl.elderly: 1 cap.once dly. approx.30 mins.aft.
       inj.as incompat.with sev. ubst.of common parenter.sols. Admin.  Contraindications: Premenopaus.endocr.status, safety in pregn.&   same meal every day.
       SC. Perform 1  admin.und.condits.where treatm.of poss.allerg./  lactat.not est., sev.liv. funct. impairm. (Child Pugh C), sev.kidn.funct.   Contraindications: Other 5α-reduct.inhibit. hypersens., women &
             st
       pseudo-allerg.reacts.immed.avail. Keep pt.und.med.observat.x30   impairm. (creatine clear.&lt;10 ml/min.), childr., lact.intol.  childr., orthostat.hypotens. hist., sev.hepat.impairm.
       mins.follow.1  admin.         Side effects: UTI, tumour pain, leucopen., anorex., incr.appet., hy-  Side effects: Impot., alter.libido, ejaculat./ breast/ psych./card./
             st
       0,25 mg: Contents of 1 vial (0,25 mg) admin.once dly.at 24 hr.interv.  percholesterolaem., gen. oed., depress., anx., nervousn., irritabil.,   disords., dizzin., allerg. reacts., loc.oed., angioed., skin reacts.incl.
       eith in morn./even. Commen. treatm. on day 5 or 6 (for morn.admin)   headache, dizzin., CNS.effs.incl. dysaesthes., memory impair., CVA,   Stev. Johns. syndr./erythema multiforme/exfoll. dermatit., alopec.,
       or day 5 (for even.admin.)of ovar.stimulat.contin. throughout gonado-  taste pervers., cataract, eye irrit., blurr.vis., palpitat., tachycard., MI,   hypertrichos., testic.pain/ swell., syncope, palpitat., rhinit., GI dis-
       tropin treatm.period incl.day of ovulat.induct.  myocard.ischaem., thrombophlebit., hypertens., pulm.embol., arter.   turbs., priapism, asthen., intra-operative floppy iris syndr., blurr.vis.,
       Contraindications: Hypersens.to any struct. analog. of GnRH/  thrombos., cerebrovasc.infarct., dyspn., GI disturbs., stomatit., dry   vis.impairm., dyspn., epistax., breast Ca, vertigo, poss.irrevers.re-
       extrins.peptide hormon/ manitol., pregn.& lactat., postmenopaus.  mouth, incr. hepat.enzym., hepatit., alopec., incr.sweat., skin re-  duc.sperm count/motil.
       women, mod. or sev.ren.& hepat.impairm.  acts.incl.tox. epiderm. necrolys., erythema multiforme, arthralg.,   Warnings and special precautions: As absorpt. through skin
       Side effects: Loc.inj.reacts., ovar.hyperstimulat. syndr,. naus., head-  myalg., arthrit., bone pain, osteoporos., incr.urin. freq., vag.bleed./-  wash affect.area immed., not recomm. with strong CYP3A4/strong
       ache, hypersens.reacts., anaphylact. reacts.  discharge/-dryn, breast pain, fatig.incl.aesthen., periph.oed., hot   or mod. CYP2D6 inhib./combin.of both/in pts.known to be poor
       Special precautions: Act./hist.of allerg. condits. or predispos.,   flush., pyrex., mucos. dryn., thirst, weight incr./loss, decr.bone min.   CYP2D6 metabolis., hepat.impairm.eff.not stud. but caut.advis.in
                             st
       poss.ovar.hyperstimulat. syndr. occur., inj.subseq.to 1  admin.by by   density at hip & lumb.spine.  liv.dis., incr.CF developm. risk in pts.with other CF risk fact., rect.
       self. admin. so long.as pt.aware of S&S of poss. hypersens. reacts.&   Special precautions: Concom.admin.of drugs whose disposit.mainly   exam./ other prost.Ca eval.bef.init.ther.& per.thereaft., new PSA
       need for immed.medic. intervent., limit.exper.dur.rep.ovar.stimulat.   depend.on P450-isoenzymes 2A6 & 2C19 & with narrow therapeut.   baseline.est.bef.init.ther.& aft.6 mnths. /monit. reg.thereaft., any
       proced. theref.admin.rep.cycles only aft.caref.risk vs. benef.evalu-  index, imp.ren.funct., no exper.in combinat.with other anti-cancer   confirm.incr.from low PSA lev.when on ther.poss.signals.pres.of
       at., admin.luteal phase support accord. to reproduct.centre’s pract.  agents., monit.bone min.density in pts.with/at risk of osteoporos at   prostat. Ca/ther.non compliance, tot.ser.PSA lev. return to baseline
       CIPLA CYPROTERONE ACETATE 50,    start of & dur. ther., osteoporos.treatm./prophylax.as appropr.  with.6 mnths.aft.ther.discont., monit. breast tiss.chang., orthostat.
                                                                  hypotens. risk/ syncope esp.init., concom.PDE5 inhib., IFIS with incr.
       Cipla Medpro [P/S]            DANOGEN, Cipla Medpro
       Cyproterone acetate           Danazol.                     complic.risk dur./aft.cataract surg., not for use with other alpha-1
                                                                  adrenerg.blocks., concom. cimetidine/ warfar., condom use advis.,
       Indications: Men: Reduct.of drive in sex.deviat., inop. prostate Ca.  Indications: Endometrios., sev.cyclic.breast pain & nodular. Males
       Women: Sev.androgenizat.      & fem: Hered.angioneurot. oed. prophylax.  ren. impairm. eff.on pharmacokin.not stud.
                                                                  Drug interactions: Incr.expos.with strong CYP3A4/ CYP2D6 in-
       (S4) TABS, 35/21.12/0293      (S5) CAPS. 34/21.12/ 0109    hib., decr.clear./incr.AUC with cimetidine, poss.incr.bld conc.in
       899089-003: 50 mg, 20, R441,62  893940-006: 100 mg, 60, R415,58  pres.of CYP3A4 inhibits., decr.clear.with verapamil/ diltiazem, incr.
       Dosage: Indiv. Admin.aft.food.  Dosage: Begin ther.on first day of menstr.cycle/ aft.pregn.exclud.   hypotens.effs.with meds.reduc.BP incl. anaesthet. agents/ PDE5
       Sex.drive reduct: Men: 1-2 tabs 2-3xdly. Maint. on low.poss.dos.1   Endometrios: Mild: 200-400 mg dly in div.dos. Mod.to sev.:   inhibits./other alpha-1 adrenerg. blocks., incr.AUC & C max with ke-
       tab/day if poss.with simultan. psychotherapeut. meas.  800 mg dly.in 2 div.dos. Maint: Titr. accord.to respons.x3-6 mnths   toconazole/ paroxetine.
       Inop.prostate Ca: Aft.orchidect: 2 tabs 1-2xdly. Without or-  with max 9 mnths. Max. of 800 mg/day. Treatm.may be rep.if sympts.   See also MDR page 360.
       chidect: 2 tabs 2-3xdly. Treatm.not to be chang./interrupt.  recur.aft.terminat.of ther.
       Women of child-bear.age: Ensure adeq.OC. Pt.to have complet.  Breast pain & nodular: 100 mg 2xdly, max. 3 mnths.  EQUISIN, Equity
       one full OC cycle bef.init. treatm. 2 tabs dly from 5th-14th day of   Hered.angioneurot.oed: Init: 400 mg dly. Aft. 2 mnth. attack-free   Exemestane
                                     period, reduc.& indiv.to low. eff.dos.
                                     Contraindications: Pregn.& lactat., thrombo-embol.disords., sev.
              Drug interferences     hepat., card.or ren.dysfunct., porphyr.
               with laboratory       Side effects: Decr.breast size, menstr. irregularit., mass gain,   All entries have been
                                     sweat., hot flush., vaginit., emot. lability, chang.in libido, acne, oily
              tests and physical     skin, deepen.of voice, clitor.hypertrophy, hirsut., musc.cramps &   compiled strictly in
                                     oed. of low.extrem., GI disturbs., CNS effs., alopec., backache, bld.
               incompatibilities     dyscras., abnorm. gluc. tol.& cholesterol irregul., hypertens., vis. dis-  accordance with
                                     turbs., IC hypertens., cholestat.jaund., skin rash, tachycard., photos-
                common with          ens. reacts. Males: testicul.atrophy & azoosperm.  current package insert
              parenteral solutions   Special precautions: Discont.treatm.if pregn. occurs, childr.&   in the publisher’s
                                     adolesc., incr.prostat.hypertrophy /prostat.Ca risk in elderly males,
                have not been        condits. advers. affect. by fluid retent.incl. migraine, card.& ren. dis.,   possession.
                                     thrombos.hist., hepat.impairm., diab.mellit., poss.anti-epilept.dos.
                  included.          adjustm., sun expos., non-hormon.contracept.advis., cert.lab.tests
                                     advis. periodic., excl.breast Ca bef.start.treatm., mammograph. &
                                     biopsy of nodul. recomm.dur. ther.if persist./enlarg.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page347.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page343.html">343</a>&nbsp;&nbsp;&nbsp;<a href="page344.html">344</a>&nbsp;&nbsp;&nbsp;<a href="page345.html">345</a>&nbsp;&nbsp;&nbsp;<a href="page346.html">346</a>&nbsp;&nbsp;&nbsp;<a href="page347.html">347</a>&nbsp;&nbsp;&nbsp;<a href="page348.html">348</a>&nbsp;&nbsp;&nbsp;<a href="page349.html">349</a>&nbsp;&nbsp;&nbsp;<a href="page350.html">350</a>&nbsp;&nbsp;&nbsp;<a href="page351.html">351</a>&nbsp;&nbsp;&nbsp;<a href="page352.html">352</a>&nbsp;&nbsp;&nbsp;<a href="page353.html">353</a>
             </td>
             <td width="35%"><a href="page349.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page349.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
